We are live on ! Find out more
EUCRW

Eucrates Biomedical Acquisition Corp. Warrant
EUCRW

Delisted

EUCRW was delisted on the 26th of April, 2023.

Back to rankings

19 hedge funds and large institutions have $2.4M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

26% more capital invested

Capital invested by funds: $1.91M → $2.4M (+$487K)

12% more funds holding

Funds holding: 17 → 19 (+2)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$245K
2
CAC
Cowen and Company
New York
+$104K
3
HM
HealthCor Management
New York
+$57.4K
4
GCL
Glazer Capital LLC
New York
+$18.5K

Top Sellers

Rank Fund Capital Flow
1
MIM
Monashee Investment Management
Massachusetts
-$71K
2
BlackRock
BlackRock
New York
-$6.1K
3
UBS Group
UBS Group
Switzerland
-$1K
4
Jane Street
Jane Street
New York
-$29
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$651K – – –
AA
2
AQR Arbitrage
Connecticut
$447K – – –
RCM
3
Radcliffe Capital Management
Pennsylvania
$325K – – –
DM
4
Deerfield Management
New York
$193K +$245K +333,333 New
BlackRock
5
BlackRock
New York
$173K -$6.1K -8,289 -3%
6CM
6
683 Capital Management
New York
$116K – – –
CAC
7
Cowen and Company
New York
$103K +$104K +140,869 +376%
ACM
8
Altium Capital Management
New York
$77K – – –
GPCM
9
Granite Point Capital Management
Massachusetts
$77K – – –
CH
10
CVI Holdings
Delaware
$69K – – –
HM
11
HealthCor Management
New York
$45K +$57.4K +78,059 New
KCM
12
Kingdon Capital Management
New York
$36K – – –
RCM
13
Rivernorth Capital Management
Florida
$19K – – –
SCM
14
Suvretta Capital Management
New York
$19K – – –
Jane Street
15
Jane Street
New York
$15K -$29 -40 -0.2%
GCL
16
Glazer Capital LLC
New York
$15K +$18.5K +25,084 New
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$13K – – –
SC
18
Sagefield Capital
Texas
$2K +$1.96K +2,666 New
Morgan Stanley
19
Morgan Stanley
New York
$1K – – –
MIM
20
Monashee Investment Management
Massachusetts
– -$71K -99,998 Closed
UBS Group
21
UBS Group
Switzerland
– -$1K -1,175 Closed

EUCRW Hedge Fund Activity: Q4 2021 in Review

19 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q4 2021, worth a combined $2.4M — up 26% from $1.91M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new EUCRW positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $245K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $71K sold.

  • 19 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q4 2021, up from 17 in Q3 2021.
  • Funds reported $2.4M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q4 2021, up 26% quarter-over-quarter.
  • 4 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q4 2021 and 2 closed out, a net change of +2 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q4 2021 was Deerfield Management, an estimated $245K added.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q4 2021 was Monashee Investment Management, an estimated $71K sold.

Based on aggregated 13F filings for Q4 2021.